{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:53:17Z","timestamp":1790268797545,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier","isbn-type":[{"value":"9780128152065","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.acc.2017.12.005","type":"book-chapter","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T11:03:52Z","timestamp":1517483032000},"page":"81-99","source":"Crossref","is-referenced-by-count":53,"title":["Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2017.12.005_bb0010","first-page":"57","article-title":"Misdiagnosis of bipolar disorder","volume":"3","author":"Singh","year":"2006","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/bs.acc.2017.12.005_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091076","article-title":"Putative transcriptional biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients","volume":"9","author":"Powell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2017.12.005_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00406-014-0557-x","article-title":"Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder","volume":"265","author":"Hashimoto","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/bs.acc.2017.12.005_bb0025","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1007\/s12035-016-0098-6","article-title":"Ratio of mBDNF to proBDNF for differential diagnosis of major depressive disorder and bipolar depression","volume":"54","author":"Zhao","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/bs.acc.2017.12.005_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11306-005-1102-8","article-title":"Metabolomics: building on a century of biochemistry to guide human health","volume":"1","author":"German","year":"2005","journal-title":"Metabolomics"},{"key":"10.1016\/bs.acc.2017.12.005_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mas.20108","article-title":"Mass spectrometry-based metabolomics","volume":"26","author":"Dettmer","year":"2007","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/bs.acc.2017.12.005_bb0040","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2008.08.026","article-title":"Metabolic phenotyping in health and disease","volume":"134","author":"Holmes","year":"2008","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2017.12.005_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/npp.2008.174","article-title":"Metabolomics: a global biochemical approach to the study of central nervous system diseases","volume":"34","author":"Kaddurah-Daouk","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.acc.2017.12.005_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","article-title":"Metabolomics tools for identifying biomarkers for neuropsychiatric diseases","volume":"35","author":"Quinones","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.acc.2017.12.005_bb0055","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1073\/pnas.1402663111","article-title":"Effect of sleep deprivation on the human metabolome","volume":"111","author":"Davies","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2017.12.005_bb0060","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.tem.2017.07.001","article-title":"Endocrinology meets metabolomics: achievements, pitfalls, and challenges","volume":"28","author":"Tokarz","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.12.005_bb0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11306-016-1094-6","article-title":"For \u201cprecision medicine and pharmacometabolomics task group\u201d-metabolomics society initiative, metabolomics enables precision medicine: \u201cA white paper, community perspective\u201d","volume":"12","author":"Beger","year":"2016","journal-title":"Metabolomics"},{"key":"10.1016\/bs.acc.2017.12.005_bb0070","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.12688\/f1000research.11495.1","article-title":"New frontiers in metabolomics: from measurement to insight","volume":"6","author":"Riekeberg","year":"2017","journal-title":"H1000Res"},{"key":"10.1016\/bs.acc.2017.12.005_bb0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/gps.1690","article-title":"A preliminary metabolomic analysis of older adults with and without depression","volume":"22","author":"Paige","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/0891988709358592","article-title":"Metabolomic differences in heart failure patients with and without major depression","volume":"23","author":"Steffens","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/bs.acc.2017.12.005_bb0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/neu.2015.59","article-title":"Increased serum levels of serine enantiomers in patients with depression","volume":"28","author":"Hashimoto","year":"2016","journal-title":"Acta. Neuropsychiatr."},{"key":"10.1016\/bs.acc.2017.12.005_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2011.22","article-title":"Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept","volume":"1","author":"Kaddurah-Daouk","year":"2011","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0095","article-title":"Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo","volume":"2","author":"Kaddurah-Daouk","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0100","article-title":"The potential biomarker panels for identification of major depressive disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis","volume":"9","author":"Ding","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2017.12.005_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.psyneuen.2016.04.017","article-title":"Purine metabolism is dysregulated in patients with major depressive disorder","volume":"70","author":"Ali-Sisto","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/bs.acc.2017.12.005_bb0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jad.2016.02.008","article-title":"Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells","volume":"195","author":"Zheng","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.acc.2017.12.005_bb0115","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1021\/pr2010082","article-title":"Plasma metabonomics as a novel diagnostic approach for major depressive disorder","volume":"11","author":"Zheng","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cca.2016.11.039","article-title":"Predictive diagnosis of major depression using NMR-based metabolomics and least-squares support vector machine","volume":"464","author":"Zheng","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2017.12.005_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165267","article-title":"Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients\u2014a multicenter pilot analysis","volume":"11","author":"Setoyama","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2017.12.005_bb0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbr.2017.06.012","article-title":"Differential urinary metabolites related with the severity of major depressive disorder","volume":"332","author":"Chen","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0135","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41598-017-03836-0","article-title":"Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study","volume":"7","author":"Hashimoto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2017.12.005_bb0140","article-title":"Purine and pyrimidine metabolism: convergent evidence on chronic antidepressant treatment response in mice and humans","volume":"6","author":"Park","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2017.12.005_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/bs.acc.2017.12.005_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2017.12.005_bb0155","doi-asserted-by":"crossref","first-page":"E1944","DOI":"10.1073\/pnas.1601532113","article-title":"Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress","volume":"113","author":"Ren","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2017.12.005_bb0160","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14728222.2016.1226284","article-title":"Soluble epoxide hydrolase: a new therapeutic target for depression","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/bs.acc.2017.12.005_bb0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.psychres.2017.02.056","article-title":"Altered soluble epoxide hydrolase-derived oxylipins in patients with seasonal major depression: an exploratory study","volume":"252","author":"Hennebelle","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0170","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Of research task force on novel biomarkers and treatments, ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0175","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/bs.acc.2017.12.005_bb0180","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1017\/S0033291716000969","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity","volume":"46","author":"Hashimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/bs.acc.2017.12.005_bb0185","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14728222.2016.1238899","article-title":"Ketamine's antidepressant action: beyond NMDA receptor inhibition","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin. Ther. Target"},{"key":"10.1016\/bs.acc.2017.12.005_bb0190","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12264-016-0081-2","article-title":"Risks associated with misuse of ketamine as a rapid-acting antidepressant","volume":"32","author":"Zhu","year":"2016","journal-title":"Neurosci. Bull."},{"key":"10.1016\/bs.acc.2017.12.005_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systemic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0205","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.biopsych.2012.11.031","article-title":"Human biomarkers of rapid antidepressant effects","volume":"73","author":"Zarate Jr","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0210","doi-asserted-by":"crossref","unstructured":"B.S. Gadad, M.K. Jha, A. Czysz, J.L. Furman, T.L. Mayes, M.P. Emslie, M.H. Trivedi, Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks, J. Affect. Disord. doi: https:\/\/doi.org\/10.1016\/j.jad.2017.07.001.","DOI":"10.1016\/j.jad.2017.07.001"},{"key":"10.1016\/bs.acc.2017.12.005_bb0215","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression","volume":"77","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0220","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.3390\/ijms16047796","article-title":"Inflammatory biomarkers as differential predictors of antidepressant response","volume":"16","author":"Hashimoto","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2017.12.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.145","article-title":"Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants","volume":"6","author":"Rotroff","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchromb.2008.05.001","article-title":"The human cerebrospinal metabolome","volume":"871","author":"Wishart","year":"2008","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2017.12.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063644","article-title":"Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics","volume":"8","author":"Trushina","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2017.12.005_bb0240","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/pr400376e","article-title":"Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry","volume":"12","author":"Blasco","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0245","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JPD-140389","article-title":"Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease","volume":"4","author":"Trupp","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/bs.acc.2017.12.005_bb0250","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1039\/C5MB00711A","article-title":"Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects","volume":"12","author":"Wuolikainen","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/bs.acc.2017.12.005_bb0255","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0260","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archgenpsychiatry.2011.1481","article-title":"Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia","volume":"69","author":"Barnes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0265","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S2215-0366(16)00097-3","article-title":"10-year trajectories of depressive symptoms and risk of dementia: a population-based study","volume":"3","author":"Mirza","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0270","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","article-title":"Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies","volume":"202","author":"Diniz","year":"2013","journal-title":"Brit. J. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.8","article-title":"Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: 3-year follow-up study","volume":"6","author":"Hashimoto","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"Hashimoto","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/bs.acc.2017.12.005_bb0285","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.pbb.2011.04.016","article-title":"Roles of glutamate signaling in preclinical and\/or mechanistic models of depression","volume":"100","author":"Tokita","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/bs.acc.2017.12.005_bb0290","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/bs.acc.2017.12.005_bb0295","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/bs.acc.2017.12.005_bb0300","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1566524015666150330143008","article-title":"Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders","volume":"15","author":"Ohgi","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/bs.acc.2017.12.005_bb0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.mp.4002130","article-title":"Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder","volume":"14","author":"Lan","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0310","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0315","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.schres.2016.10.037","article-title":"Neurobiological basis of bipolar disorder: mitochondrial dysfunction hypothesis and beyond","volume":"187","author":"Kato","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0320","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1471-4159.1981.tb01608.x","article-title":"Postmortem changes of amino compounds in human and rat brain","volume":"36","author":"Perry","year":"1981","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2017.12.005_bb0325","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1021\/ac901502j","article-title":"Metabolic profiling of human blood serum from treated patients with bipolar disorder employing 1H NMR spectroscopy and chemometrics","volume":"81","author":"Sussulini","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.acc.2017.12.005_bb0330","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1021\/ac900675k","article-title":"Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry","volume":"81","author":"Soga","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.acc.2017.12.005_bb0335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbacli.2016.03.008","article-title":"Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder","volume":"5","author":"Yoshimi","year":"2016","journal-title":"BBA Clin."},{"key":"10.1016\/bs.acc.2017.12.005_bb0340","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/pcn.12461","article-title":"Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis","volume":"71","author":"Kageyama","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/bs.acc.2017.12.005_bb0345","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1039\/c3mb70614a","article-title":"2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder","volume":"10","author":"Xu","year":"2014","journal-title":"Mol. Biosyst."},{"key":"10.1016\/bs.acc.2017.12.005_bb0350","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1038\/srep05855","article-title":"Combined application of NMR- and GC\u2013MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder","volume":"4","author":"Chen","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2017.12.005_bb0355","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/mp.2015.217","article-title":"Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis","volume":"21","author":"Yoshimi","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.acc.2017.12.005_bb0360","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/jnr.21691","article-title":"Localization of N-methyl-norsalsolinol within rodent and human brain","volume":"86","author":"DeCuypere","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0365","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/bph.12494","article-title":"A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks","volume":"171","author":"Villase\u00f1or","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.acc.2017.12.005_bb0370","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s11306-013-0508-y","article-title":"Novel urinary biomarkers for diagnosing bipolar disorder","volume":"9","author":"Zheng","year":"2013","journal-title":"Metabolomics"},{"key":"10.1016\/bs.acc.2017.12.005_bb0375","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"L\u00f6ffler","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/bs.acc.2017.12.005_bb0380","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2014.11.001","article-title":"Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls","volume":"25","author":"P\u00e5lsson","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.acc.2017.12.005_bb0385","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1021\/acs.jproteome.5b00434","article-title":"Divergent urinary metabolic phenotypes between major depressive disorder and bipolar disorder identified by a combined GC\u2013MS and NMR spectroscopic metabonomic approach","volume":"14","author":"Chen","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0390","doi-asserted-by":"crossref","unstructured":"G. Scola, A.C. Andreazza, L.T. Young, A comparative expression analysis of isocitrate dehydrogenase-3 gene and protein levels in postmortem brain tissues from subjects with bipolar disorder, Mol. Psychiatry doi: https:\/\/doi.org\/10.1038\/mp.2017.149.","DOI":"10.1038\/mp.2017.149"},{"key":"10.1016\/bs.acc.2017.12.005_bb0395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpsychires.2014.12.007","article-title":"Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings","volume":"61","author":"Levin","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/bs.acc.2017.12.005_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600800","article-title":"Loss-of-function variants influence the human serum metabolome","volume":"2","author":"Yu","year":"2016","journal-title":"Sci. Adv."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:35:31Z","timestamp":1758742531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242317300707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128152065"],"references-count":79,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2017.12.005","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}